Immunogenicity of recombinant hepatitis B vaccine in treatment-na&iuml;ve and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment

doi:10.3748/wjg.v12.i27.4420

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 27

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2207)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

239

HTML

1677

Figures (1-1)

166

Tables (1-1)

125

Sum=2207

Jul 21, 2006 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jul 21, 2006; 12(27): 4420-4424
Published online Jul 21, 2006. doi: 10.3748/wjg.v12.i27.4420

Open in New Tab Full Size Figure Download Figure

Figure 1 Anti-HBs antibody response rates between group-1 and group-2 CHC patients at one month following every dose of the vaccine (mo 1, 2, and 7).

Citation: Elefsiniotis IS, Vezali E, Kamposioras K, Pantazis KD, Tontorova R, Ketikoglou I, Moulakakis A, Saroglou G. Immunogenicity of recombinant hepatitis B vaccine in treatment-naïve and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol 2006; 12(27): 4420-4424
URL: https://www.wjgnet.com/1007-9327/full/v12/i27/4420.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i27.4420